{
    "clinical_study": {
        "@rank": "159947", 
        "acronym": "SPARC", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Radiotherapy"
        }, 
        "brief_summary": {
            "textblock": "Giving a higher dose of radiation to the dominant tumour nodule within the prostate is\n      hypothesized to improve tumour control. This trial will assess whether this technique,\n      delivered in 5 treatments, can be delivered without increasing side effects."
        }, 
        "brief_title": "The SPARC Trial: Stereotactic Prostate Ablative Radiotherapy Using Cyberknife", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Aim To assess if a focal boost can be delivered to the dominant tumour nodule alongside\n      36.25 Gy in 5 fractions to the whole prostate gland.\n\n      Primary end-point:   Acute toxicity (Radiation Therapy Oncology Group (RTOG), International\n      prostate symptom score (IPSS))\n\n      Secondary end-points:  Prostate specific antigen (PSA) nadir and 2-year biochemical control\n      Late toxicity (IPSS, RTOG, International index of erectile function (IIEF-5)) Quality of\n      life (EQ5D scale)\n\n      Inclusion criteria\n\n        -  Prostate cancer patients with any of the following:\n\n        -  PSA>20\n\n        -  Gleason grade 4+3 or higher\n\n        -  Stage T3a\n\n        -  Exclusion criteria\n\n        -  Nodal or metastatic disease\n\n        -  PSA>40\n\n        -  Stage T3b or higher\n\n      Study interventions\n\n      This is a phase II study which will recruit 20 patients. A dose of 36.25 Gy in 5 fractions\n      will be delivered to the whole prostate with a simultaneous integrated boost up to 47.5 Gy\n      in 5 fractions or to the highest dose possible within dose constraints. The boost volume\n      will be defined on the multiparametric magnetic resonance scan by the specialist\n      radiologist."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Prostate cancer patients with any of the following:\n\n          -  PSA 20-40\n\n          -  Gleason grade 4+3 or higher\n\n          -  Stage T3a\n\n        Exclusion Criteria:\n\n          -  Nodal or metastatic disease\n\n          -  PSA>40\n\n          -  Stage T3b or higher"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145494", 
            "org_study_id": "13/LO/0109", 
            "secondary_id": "CCR 3923"
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "description": "Stereotactic body radiotherapy (SBRT) to the whole prostate (36.25 Gy in 5 fractions) with a focal boost (47.5 Gy in 5 fractions) to the MRI-defined dominant tumour nodule.", 
            "intervention_name": "Radiotherapy", 
            "intervention_type": "Radiation", 
            "other_name": "Cyberknife"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "SBRT (stereotactic body radiotherapy)", 
            "Focal boost", 
            "Prostate"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "contact": {
                "email": "daniel.henderson@rmh.nhs.uk", 
                "last_name": "Daniel R Henderson, FRCR"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "SW3 6JJ"
                }, 
                "name": "Royal Marsden NHS Foundation trust"
            }, 
            "investigator": [
                {
                    "last_name": "Nicholas J van As, FRCR", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Alison C Tree, FRCR", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "Stereotactic Prostate Augmented Radiotherapy With Cyberknife", 
        "overall_contact": {
            "last_name": "Nicholas J van As, FRCR", 
            "phone": "02078118336"
        }, 
        "overall_contact_backup": {
            "last_name": "Daniel R Henderson, FRCR", 
            "phone": "02078118469"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Research Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "RTOG scale acute GU toxicity will be measured at baseline, end of treatment, then 2,4 and 12 weeks post treatment. The maximal toxicity during follow up is the primary outcome measure.", 
            "measure": "Acute genitourinary(GU) toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "Maximal recorded toxicity within the acute toxicity period (up to 12 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145494"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "RTOG scale", 
                "measure": "Acute gastrointestinal (GI) toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Within 12 weeks of treatment completion"
            }, 
            {
                "description": "RTOG scale", 
                "measure": "Late GI and GU toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "From 12 weeks until study completion"
            }, 
            {
                "description": "IPSS, IIEF-5 and EQ5-D", 
                "measure": "Patient reported outcomes i.e. IPSS, IIEF-5 and EQ5-D", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 12 weeks, 12 months and 6 monthly to 5 years"
            }, 
            {
                "description": "PSA will be measured 3-6 monthly during study", 
                "measure": "Biochemical relapse-free survival", 
                "safety_issue": "No", 
                "time_frame": "Measured at 12 weeks after completion of treatment and 3-6 monthly to 5 years thereafter"
            }
        ], 
        "source": "Royal Marsden NHS Foundation Trust", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Royal Marsden NHS Foundation Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}